Niagen Bioscience (NASDAQ:NAGE – Get Free Report) had its price target boosted by investment analysts at Canaccord Genuity Group from $13.00 to $16.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 19.14% from the company’s current price.
Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Friday. Roth Capital lifted their target price on Niagen Bioscience from $10.00 to $23.00 and gave the company a “buy” rating in a research report on Friday.
Get Our Latest Stock Analysis on NAGE
Niagen Bioscience Stock Performance
About Niagen Bioscience
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Recommended Stories
- Five stocks we like better than Niagen Bioscience
- Most active stocks: Dollar volume vs share volume
- Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
- What Are Dividend Challengers?
- As Gold Surges, Albemarle Stock May Be the Next to Pop
- What is the Hang Seng index?
- Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming?
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.